Inflammatory Biomarkers and Cardiovascular Risk Assessment. Current Knowledge and Future Perspectives

Author(s): Elisavet Moutzouri, Vasilis Tsimihodimos, Alexandros D. Tselepis

Journal Name: Current Pharmaceutical Design

Volume 19 , Issue 21 , 2013

Become EABM
Become Reviewer

Abstract:

Cardiovascular disease is the leading cause of morbidity and mortality in the Western world. However, it appears that currently available risk assessment tools often underestimate risk, especially for patients in the intermediate-risk category. Considering the socioeconomic cost, it is imperative to correctly identify patients in the intermediate-risk category who would benefit from more aggressive treatment. A plethora of experimental and observational studies provide support that lipoprotein associated phospholipase A2 (Lp- PLA2) and secretory phospholipases A2 (sPLA2) as well as high sensitivity C-reactive protein (hsCRP) are useful biomarkers of cardiovascular risk. Particularly, Lp-PLA2) has also been addressed as pharmacological target and we are eagerly awaiting the results of ongoing phase III clinical trials. In this review we discuss the current literature regarding the pros and cons of these biomarkers.

Keywords: Atherosclerosis, biomarkers, cardiovascular disease, hsCRP, inflammation, Lp-PLA2, PAF-acetylhydrolase, sPLA2.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 19
ISSUE: 21
Year: 2013
Page: [3827 - 3840]
Pages: 14
DOI: 10.2174/13816128113199990307
Price: $65

Article Metrics

PDF: 37